Pfizer, BioNTech reach deal to supply EU with 200 million doses of its COVID-19 vaccine candidateMarket Watch • 11/11/20
Pfizer and BioNTech Reach an Agreement to Supply the EU With 200 Million Doses of Their BNT162b2 mRNA-Based Vaccine Candidate Against SARS-CoV-2Business Wire • 11/11/20
Causeway Capital Commentary- Update on Covid019 Vaccines: A Major Breakthrough for mRNA TechnologyGuruFocus • 11/10/20
Everything you need to know about BioNTech and the married couple behind the COVID-19 vaccine at the front of a global raceMarket Watch • 11/10/20
No Surprise Here: BioNTech's Q3 Results Driven by Its COVID-19 Vaccine ProgramThe Motley Fool • 11/10/20
BioNTech Announces Third Quarter 2020 Financial Results and Corporate ProgressGlobeNewsWire • 11/10/20
U.S. health officials 'very optimistic' Pfizer coronavirus vaccine and others 'could effectively end the pandemic'CNBC • 11/09/20
BioNTech COVID-19 Vaccine Sets Up >50% Annual Yield With 19% Downside ProtectionSeeking Alpha • 11/09/20